Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections

Trial Profile

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial skin diseases; Gram-positive infections; Skin infections
  • Focus Adverse reactions
  • Sponsors Allergene
  • Most Recent Events

    • 08 Aug 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 01 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top